Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best cheap strong buy stocks to buy now. Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on August 18, setting a price target of $29.00.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its fiscal Q2 2025 results on July 30, stating that it is on track to attain a 30% operating profit margin by 2027 in line with its Pivot to Growth Strategy.

Fiscal Q2 2025 marked the tenth consecutive quarter of year-over-year revenue growth for the company, with revenues reaching $4.2 billion.

GAAP diluted EPS for the quarter was $0.24, while non-GAAP diluted EPS reached $0.66, reflecting a growth of $0.05 or 9% year-over-year.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) also reported a 47% year-over-year growth in free cash flow, reaching $476 million.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments.

Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.